Wednesday, November 16, 2016

BRIEF-Amgen announces Erenumab significantly reduces monthly migraine days in patients with episodic migraine in second phase 3 study

* Amgen announces Erenumab significantly reduces monthly

migraine days in patients with episodic migraine in second phase

3 study

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)